← Eichor
Study identifier: NCT06593977 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Evaluation of Dynavisc in Pain Reduction Following Revision Surgery for Persistent or Recurrent Carpal Tunnel Syndrome

Condition: Carpal Tunnel Syndrome (CTS)  ·  Sponsor: FzioMed

PhaseNA
Planned participants50
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

The trial will evaluate the efficacy of DYNAVISC in subjects with a diagnosis of persistent or recurrent carpal tunnel syndrome. This is a prospective, multicenter, randomized, evaluator-blinded clinical trial. Results will be stratified based on the method used for median nerve coverage: Group 1 (standard of care surgery followed by DYNAVISC surrounding the median nerve, n=25 participants), Group 2 (standard of care surgery followed by coverage of the median nerve with a hypothenar fat pad flap, n=25

This description comes directly from the study's public registry record.

Talk to the study team

Gere diZerega, MD  ·  805-630-2800  ·  gdizerega@fziomed.com

Stephanie Cortese, MS  ·  8054411968  ·  scortese@fziomed.com

Always discuss trial participation with your own doctor first.

Locations (4)

UZ LeuvenLeuven, Belgium, BelgiumRecruiting
AZ DeltaRoeselare, Belgium, BelgiumRecruiting
Hospital Angelina CaronAraçatuba, Brazil, BrazilRecruiting
Azienda Ospedale Universita PadovaPadova, Italy, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06593977